Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Nemolizumab (Nemluvio)

decorative image of the issue cover

Published May 27, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nemolizumab powder and solvent for subcutaneous injection, available as:
    • 30 mg/0.49 mL in a single-dose prefilled dual-chamber pen
    • 30 mg/0.49 mL in a single-dose prefilled dual-chamber syringe with copackaged needle.
  • Indication: For the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.